Bengaluru-Based Leucine Rich Bio Secures Pre-Series A Funding for Healthcare Innovation

With this strategic investment, Leucine Rich Bio aims to expand its product portfolio and bolster its research and development capabilities.

Bengaluru-based Leucine Rich Bio, a microbiome company, has successfully secured an undisclosed funding in a Pre-Series A round. 

This funding initiative was driven by medical professionals, including gastroenterologists, oncologists, and biotech entrepreneurs.

The primary objective of this funding is to enable the creation of new healthcare products and enhance the company's branding. With this strategic investment, Leucine Rich Bio aims to expand its product portfolio and bolster its research and development capabilities.

Commenting on the same, Kumar Sankaran, CEO of Leucine Rich Bio, said, "We firmly believe in the potential of microbiome research to revolutionize healthcare, particularly in the domain of cancer treatment. With this backing, we can make substantial progress in our mission to harness the microbiome's power in addressing various chronic diseases and cancer."

Leucine Rich Bio, headquartered in Bengaluru, is considered South Asia's first microbiome business. Since its inception in 2014, the company has been a leader in developing advanced analytics tools for genomics data analysis and interpretation.

Under its brand, Leucine Rich Bio plans to introduce new supplements based on Indian microbiome data, targeting various diseases and conditions.

In other funding news in the healthcare sector, Mestastop Solutions, a biotechnology startup based in Bangalore, recently secured INR 4.5 Cr (approximately $500,000) in a Pre-Series A funding round. 

This round was led by a group of 92 angel investors and received support from Malpani Ventures. It is worth noting that the company had previously secured seed funding of INR 2 Cr in 2021, with the backing of IIM Ahmedabad's CIIE and participation from IKP and several angel investors.

The funds raised by Mestastop Solutions will be directed towards generating proof of concept data related to small molecules targeting the first-in-class identified targets.